Navigation Links
Reportlinker Adds Global HIV Drugs industry
Date:5/17/2010

NEW YORK, May 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global HIV Drugs industry

http://www.reportlinker.com/p0197175/Global-HIV-Drugs-industry.html

This report analyzes the Worldwide markets for HIV Drugs in US$ Million. The report provides separate comprehensive analytics for US, Canada, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 52 companies including Abbott Laboratories, Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Koronis Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Tibotec BVBA, ViiV Healthcare, and VIRxSYS Corp. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

HIV DRUGS MCP-6176

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. GLOBAL OUTLOOK II-1

Antiretroviral Drug Market Flourishes II-1

US Leads the Global HIV Drugs Market II-1

NRTIs - The Largest Selling Drug Class Worldwide II-2

HIV Prevalence on the Rise II-2

Table 1: Global Prevalence of HIV Infection by Region (2007 &

2008) in Millions (includes corresponding Graph/Chart) II-2

Table 2: Global Incidence of HIV Infection by Region (2007 &

2008) in Thousands (includes corresponding Graph/Chart) II-3

Table 3: Global HIV Related Deaths by Region (2007 & 2008) in

Thousands (includes corresponding Graph/Chart) II-4

Table 4: Global Distribution of HIV Prevalence, Incidence and

Mortality by Age Group (2008) (In Millions) (includes

corresponding Graph/Chart) II-4

Table 5: HIV Prevalence in Select Countries (2007) (includes

corresponding Graph/Chart) II-5

Antiretroviral Drugs - The Lone Treatment Option for HIV and AIDS II-6

Protease Inhibitors II-6

Select Protease Inhibitors; Dosing and Frequency II-7

Table 6: Leading Protease Inhibitors Drugs Worldwide (2006):

Value Breakdown for Kaletra, Reyataz, Norvir,

Agenerase/Lexiva, Viracept and Others (includes

corresponding Graph/Chart) II-7

Overview of Select Protease Inhibitors II-7

Kaletra (lopinavir/ritonavir) II-7

Reyataz (Atazanavir) II-7

Prezista (Darunavir) II-8

Viracept (nelfinavir mesylate) II-8

Kaletra and Reyataz to Maintain Market Dominance II-8

Nucleoside Reverse Transcriptase Inhibitors II-9

Approved NRTI Drugs; Dosing and Frequency II-9

Overview of Select NRTIs II-9

Emtriva (emtricitabine) II-9

Stavudine (Zerit)- Marred with Safety Issues II-9

Safety Concerns to Curb Ziagen's Use II-10

Non-Nucleoside Reverse Transcriptase Inhibitors II-10

Overview of Select NNRTIs II-10

Viramune® (nevirapine) II-10

Intelence (Etravirine) II-10

Integrase Inhibitors II-11

Overview of Select Integrase Inhibitors II-11

Isentress (Raltegravir) II-11

Elvitegravir (Gilead Sciences) II-11

Chemokine Receptor 5 Inhibitors II-11

Selzentry (maraviroc) II-12

Selzentry Makes a Slow Start II-12

Fusion Inhibitors II-12

Combination Therapy II-13

Drug Resistance Issues Fuel Use of Combination Therapy II-13

Atripla (Bristol-Myers Squibb and Gilead Sciences) II-14

Epzicom (GlaxoSmithKline) II-14

Quad (Gilead Sciences) II-14

Drug Pipeline Laden With Efficacious Drugs and Novel Drug Classes II-15

Abandoned Trials in Recent Years II-15

Select Antiretroviral Pipeline Drugs II-16

HIV Drug Usage Picks Up; Major Population Still Lacks

Accessibility II-16

ART Penetration Posts Significant Growth in Recent Years II-17

Table 7: HIV-Infected Population Receiving Anti-Retroviral

Treatment in Low and Middle Income Countries (2004 - 2008)

(In Millions) (includes corresponding Graph/Chart) II-17

Table 8: HIV-Infected Population Receiving and In Need of

Anti-Retroviral Treatment in Low and Middle Income Countries

By Region (2008) (includes corresponding Graph/Chart) II-18

Table 9: Number of HIV Patients Receiving Antiretroviral

Drugs in Select Low- and Middle-Income Countries (2008)

(includes corresponding Graph/Chart) II-19

Table 10: Number of HIV Patients Receiving Antiretroviral

Drugs in Select Low- and Middle-Income Countries By Gender

(2008) (includes corresponding Graph/Chart) II-20

Table 11: Number of HIV Patients Receiving Antiretroviral

Drugs in Select Low- and Middle-Income Countries By Age

Group (2008) (includes corresponding Graph/Chart) II-21

Table 12: Number of HIV Patients Receiving Antiretroviral

Drugs in Select High-Income Countries (2008) (includes

corresponding Graph/Chart) II-22

Number of Children and Pregnant Women on ART Rises Dramatically II-23

Table 13: HIV-Infected Children Receiving and In Need of

Anti-Retroviral Treatment in Low and Middle Income Countries

By Region (2008) (includes corresponding Graph/Chart) II-23

Table 14: HIV-Infected Pregnant Women Receiving and In Need

of Anti-Retroviral Treatment in Low and Middle Income

Countries By Region (2008) (includes corresponding

Graph/Chart) II-24

Convenience and Efficacy - Key Growth Drivers II-24

Antiretrovirals as Preventive Medicine II-25

Cost of ARTs - A Major Barrier to Widespread Access II-25

Manufacturers Hindering Entry of Generics II-25

Indian Drug Manufactures Propose to Offer Low Cost Generic

Versions II-26

Need for Novel Drugs Continues II-26

Development of Vaccines for HIV - A Challenging Task II-26

Immune-Based Therapies Bode Promising Treatment Options for

Future II-27

Injecting Drug Users and HIV II-27

2. COMPETITIVE SCENARIO II-28

HIV Drug Industry - Rife With Activity II-28

Gilead Reaches the Top, While GSK Scrambles to Gain Lost Ground II-28

Table 15: Leading Companies in Global HIV Drugs Market (2005,

2007 & 2009): Percentage Breakdown of Revenues for Gilead

Sciences, GlaxoSmithKline, Bristol-Myers Squibb and Others

(includes corresponding Graph/Chart) II-29

Truvada Reigns Global HIV Drug Market; Atripla Fast Catching Up II-29

Table 16: Worldwide Sales of Select Leading HIV Drugs

(2006-2008) (includes corresponding Graph/Chart) II-30

Atripla to Ease Truvada's Revenue Growth II-31

Atripla's Success Propels Gilead's Market Share Above GSK II-31

3. DISEASE OVERVIEW II-32

HIV - An Overview of the Deadly Virus II-32

Unique Genetic Variability of HIV II-32

Origin of HIV II-34

Types of HIV Virus II-34

HIV Transmission II-34

Sexual Route II-34

Blood Products or Blood II-34

Mother-to-Child II-35

Human Immune System and HIV Interaction II-35

Stages of HIV Infection II-35

Acute Stage of HIV Infection II-36

Latency Stage II-36

AIDS - Acquired Immune Deficiency Syndrome II-37

Symptoms of HIV and AIDS Infection II-37

HIV Testing II-38

Diagnostic Tests for HIV and AIDS Infection II-39

HIV Treatment II-39

4. RECENT DRUG APPROVALS II-41

Pfizer Obtains Expanded Indication for Selzentry from FDA II-41

Tibotec Obtains Traditional Approval for Intelence® II-41

FDA Confers Tentative Approval for Generic Efavirenz Tablets II-41

FDA Clears New Dosing Recommendations for Retrovir Syrup for

Infants II-42

FDA Confers Tentative Approval for Lamivudine and Tenofovir df

Tablets II-42

Abbott Obtains EC Approval for Once-daily Dosage of Kaletra® II-42

Merck Obtains Expanded indication for Isentress®, for use in

Treatment-Naïve HIV Patients II-43

Tibotec Obtains FDA Clearance for Using Prezista in Pediatric

Patients II-43

Tibotec Obtains EU Approval for Once-daily Dosing of Prezista II-43

Pfizer Receives FDA Clearance for Marketing Selzentry™ II-44

BMS Obtains FDA Approval for REYATAZ®/r Combination Therapy II-44

EU Clears Tibotec's Intelence™ in HIV Combination Therapy II-44

Boehringer Obtains FDA Approval for Aptivus® OS II-45

Abbott Obtains EC Approval for Lower-Strength Kaletra for

Pediatric Use II-45

5. RECENT INDUSTRY ACTIVITY II-46

Gilead Completes Phase II Trial on Single-Dose HIV Drug, Quad II-46

Gilead Completes Phase II Trial on Cobicistat Boosting Agent,

Cobicista II-46

Merck to Refrain from Filing NDA for Vicriviroc in Treatment-

Experienced HIV-Patients II-47

Merck's Isentress® Receives U.S. DHHS Recommendation for Use

in Treatment-Naïve Patients II-47

GSK and Pfizer Launch ViiV Healthcare II-47

GSK and Idenix to Co-Develop New HIV Drug II-48

Avexa Enters into Agreement with Tibotec II-48

Gilead Enters into Agreement with Piramal Lifesciences II-49

Avexa to Merge with Progen II-49

Myriad Acquires Bevirimat II-49

Vironova Signs Agreement with UMBC II-49

Ceragenix Signs License Agreement with FPBT II-49

Medivir to Transfer Alovudine License and IP to Beijing Mefuvir II-50

Gilead Sciences and Merck Ink Distributing Agreement for Atripla II-50

Boehringer Commences New Clinical Trial for Viramune® XR II-51

EC Reinstates Marketing Authorization for Viracept II-51

Virax Bags Additional Patent for HIV Vaccine, VIR201 II-51

6. FOCUS ON SELECT GLOBAL PLAYERS II-52

Abbott Laboratories (US) II-52

Boehringer Ingelheim GmbH (Germany) II-52

Bristol-Myers Squibb Company (US) II-53

F. Hoffmann-La Roche Ltd. (Switzerland) II-54

Gilead Sciences, Inc. (US) II-54

Koronis Pharmaceuticals, Inc. (US) II-55

Merck & Co., Inc. (US) II-55

Pfizer, Inc. (US) II-56

Tibotec BVBA (Belgium) II-56

ViiV Healthcare (UK) II-57

VIRxSYS Corp. (US) II-57

7. GLOBAL MARKET PERSPECTIVE II-58

Table 17: World Recent Past, Current & Future Analysis for HIV

Drugs by Geographic Region - US, Canada, Japan, Europe and

Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) II-58

Table 18: World 10-Year Perspective for HIV Drugs by

Geographic Region - Percentage Breakdown of Dollar Revenues

for US, Canada, Japan, Europe and Rest of World Markets for

Years 2006, 2009, & 2015 (includes corresponding Graph/Chart) II-59

Table 19: World Recent Past, Current & Future Analysis for HIV

Drugs by Product Segment - NRTIs, NNRTIs, PIs and Others

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-60

Table 20: World 10-Year Perspective for HIV Drugs by Product

Segment- Percentage Breakdown of Dollar Revenues for NTRIs,

NNTRIs, PIs and Others Markets for Years 2006, 2009, & 2015

(includes corresponding Graph/Chart) II-61

III. MARKET

1. UNITED STATES III-1

A.Market Analysis III-1

HIV Drugs Market Continues to Prosper III-1

NRTIs Maintain the Lead III-1

Select FDA-Approved Antiretroviral Drugs and Approval Date III-1

Patent Expiries of Select Antiretroviral Drugs in the US

(2010 and Beyond) III-2

Atripla Tops US HIV Drug Chart III-3

Table 21: Leading HIV/AIDS Drugs in the US Market (2008)

in US$ Million (includes corresponding Graph/Chart) III-4

NRTIs Losing Share In Total Prescriptions; Top Spot Remains

Intact III-4

Table 22: Percentage Breakdown of US Total Prescriptions

of HIV Drugs By Class (2004-2008) (includes corresponding

Graph/Chart) III-5

Gilead Takes the Lead In NRTI Prescriptions III-5

Table 23: Percentage Breakdown of US Total Prescriptions

of NRTIs By Company (2004-2007) (includes corresponding

Graph/Chart) III-6

Table 24: Percentage Breakdown of US Total Prescriptions

of NRTIs By Drug (2006-2007) (includes corresponding

Graph/Chart) III-6

Atripla Leads in Treatment-Naïve HIV Market III-7

Table 25: Leading Drugs in Treatment-Naive HIV Patient

Therapeutic Market (2007) (includes corresponding

Graph/Chart) III-7

Patent Expiries to Dent Sales of GSK III-7

Drug Assistance Programs Take the Brunt of Recession III-7

New Drug Approvals III-8

Strategic Corporate Developments III-11

Select Players in the Region III-14

B.Market Analytics III-18

Table 26: US Recent Past, Current & Future Analysis for HIV

Drugs by Product Segment - NRTIs, NNRTIs, PIs and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-18

Table 27: US 10-Year Perspective for HIV Drugs by Product

Segment- Percentage Breakdown of Dollar Revenues for NTRIs,

NNTRIs, PIs and Others Markets for Years 2006, 2009, & 2015

(includes corresponding Graph/Chart) III-19

2. CANADA III-20

A.Market Analysis III-20

Current and Future Analysis III-20

Approval Delays Daunting Drug Access III-20

A Peek into the Canadian Drug Regulatory Environment III-20

PI Drugs Continue to Witness Growth III-21

Table 28: Canadian Sales of Protease Inhibitor Drugs (2007

& 2008) in US$ Million (includes corresponding Graph/Chart) III-21

Select Approved Antiretroviral Drugs in Canada (1995-2006) III-21

B.Market Analytics III-22

Table 29: Canadian Recent Past, Current & Future Analysis

for HIV Drugs with Annual Revenue Figures in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-22

3. JAPAN III-23

A.Market Analysis III-23

Japan - The Fastest Growing Market for HIV Drugs Worldwide III-23

Funding Scenario in Japan III-23

B.Market Analytics III-23

Table 30: Japanese Recent Past, Current & Future Analysis

for HIV Drugs with Annual Revenue Figures in US$ Million for

Years 2006 through 2015 (includes corresponding Graph/Chart) III-23

4. EUROPE III-24

A.Market Analysis III-24

Demand for HIV Drugs Continues to Rise III-24

European HIV Drug Market - An Overview III-24

Delayed Diagnosis - A Major Impediment to Increase in Survival III-24

Limiting Factors Hitting Growth Prospects Hard III-25

Number of New Patients Rises, While Discontinuation Rates

Plummet in Leading Markets III-25

Table 31: HIV Drugs Market in Leading EU Countries (2006):

Percentage Breakdown for Italy, Spain, France, United

Kingdom and Germany (includes corresponding Graph/Chart) III-26

HAART Continues to Gain Market Share III-26

New Drug Approvals III-26

Strategic Corporate Developments III-28

Select Players in the Region III-31

B.Market Analytics III-33

Table 32: European Recent Past, Current & Future Analysis

for HIV Drugs with Annual Revenue Figures in US$ Million for

Years 2006 through 2015 (includes corresponding Graph/Chart) III-33

5. REST OF WORLD III-34

A.Market Analysis III-34

Current and Future Analysis III-34

Funding Gap Threatens to Put Patients at Risk III-34

Drugs Resistance Prompts Chinese Government to Launch Novel

Drugs III-34

Strategic Corporate Developments III-35

B.Market Analytics III-35

Table 33: Rest of World Recent Past, Current & Future

Analysis for HIV Drugs with Annual Revenue Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-35

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 52 (including Divisions/Subsidiaries - 61)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 34

Canada 1

Europe 13

Germany 2

The United Kingdom 5

Spain 1

Rest of Europe 5

Asia-Pacific (Excluding Japan) 13

------------------------------------------

To order this report:

Drug and Medication Industry: Global HIV Drugs industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets
2. Reportlinker Adds Antifungal Drugs: Technologies and Global Markets
3. Reportlinker Adds The World Anesthesia Drug Market
4. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
5. Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025
6. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
7. Reportlinker Adds Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
8. Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey)
9. Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
10. Reportlinker Adds World Wound Management Products
11. Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...   Bernstein Liebhard LLP today announced that a ... District Court for the District of Arizona ... all persons or entities who purchased common shares of Insys ... from March 3, 2015 through January 25, 2016 (the "Class ... with violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 2016  Montoya Love is recognized by Continental Who,s ... Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range ... provides healthcare institutions, clinical laboratories and life science researchers ... the globe. ...
(Date:2/4/2016)... -- Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) ... Chronic Obstructive Pulmonary Disease (COPD) is a ... airways and lungs. Persistent breathing difficulties and repeated ... of the leading causes of morbidity and the ... is linked to cumulative exposure to risk factors, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... recognition of National Wear Red Day. National Wear Red Day is the first ... in women. Heart disease and stroke cause 1 in 3 deaths among women each ...
(Date:2/6/2016)... ... 06, 2016 , ... US Sports Camps is proud to sponsor the Bay ... together top non-profit leaders, ultimate organizations, and coaches from around the US. The theme ... Disc Program Director of Youth and Education, describes this year YUCC as “an important ...
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
Breaking Medicine News(10 mins):